5 results on '"Bernd Heinz"'
Search Results
2. The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma.
- Author
-
Hartmann S, Plütschow A, Mottok A, Bernd HW, Feller AC, Ott G, Cogliatti S, Fend F, Quintanilla-Martinez L, Stein H, Klapper W, Möller P, Rosenwald A, Engert A, Hansmann ML, and Eichenauer DA
- Subjects
- Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biopsy, Combined Modality Therapy, Female, Follow-Up Studies, Germany epidemiology, Hematopoietic Stem Cell Transplantation, Hodgkin Disease drug therapy, Hodgkin Disease epidemiology, Hodgkin Disease radiotherapy, Humans, Male, Recurrence, Rituximab therapeutic use, Transplantation, Autologous, Disease-Free Survival, Hodgkin Disease pathology
- Abstract
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) can present with different histopathological growth patterns. The impact of these histopathological growth patterns on relapse characteristics is unknown. We therefore analyzed paired biopsies obtained at initial diagnosis and relapse from 33 NLPHL patients who had received first-line treatment within German Hodgkin Study Group (GHSG) trial protocols, and from a second cohort of 41 relapsed NLPHL patients who had been treated outside GHSG studies. Among the 33 GHSG patients, 21 patients presented with a typical growth pattern at initial diagnosis, whereas 12 patients had a variant histology. The histopathological growth patterns at initial diagnosis and at relapse were consistent in 67% of cases. A variant histology at initial diagnosis was associated with a shorter median time to lymphoma recurrence (2.8 vs 5.2 years; P = .0219). A similar tendency towards a shorter median time to lymphoma recurrence was observed for patients presenting with a variant histology at relapse, irrespective of the growth pattern at initial diagnosis. Results obtained from the 41 NLPHL patients who had been treated outside GHSG studies were comparable (median time to lymphoma recurrence for variant histology vs typical growth pattern at initial diagnosis: 1.5 vs 7.0 years). In conclusion, the histopathological growth pattern remains consistent at relapse in the majority of NLPHL cases, and has major impact on the time of relapse., (© 2019 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
3. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).
- Author
-
Hartmann S, Eichenauer DA, Plütschow A, Mottok A, Bob R, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller AC, Ott G, Möller P, Rosenwald A, Stein H, Hansmann ML, Engert A, and Klapper W
- Subjects
- Adult, Databases, Factual, Education, Medical, Continuing, Female, Follow-Up Studies, Germany, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Recurrence, Local mortality, Neoplasm Recurrence, Local pathology, Neoplasm Staging, Predictive Value of Tests, Prognosis, Risk Factors, B-Lymphocytes pathology, Hodgkin Disease mortality, Hodgkin Disease pathology
- Abstract
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for approximately 5% of all Hodgkin lymphoma cases. The aim of this study was to evaluate the prognostic implication of histopathologic NLPHL variants. Biopsies of 423 NLPHL patients treated within 9 prospective clinical trials performed by the German Hodgkin Study Group were classified as tumor cell-rich cases (n = 10), typical NLPHL (n = 308), or histopathologic variants (n = 105). Histopathologic variants were characterized by the presence of lymphoma cells outside the B-cell nodules or B-cell depletion of the microenvironment. Compared with typical NLPHL, histopathologic variants were associated with advanced disease (29.5% vs 14.6%, P = .0012) and a higher relapse rate (18.1% vs 6.5% at 5 years, P = .0009). Variant histology represented an independent prognostic factor (odds ratio = 2.955) in a multivariate model of progression/relapse. A prognostic score, including the risk factors variant histopathologic growth pattern, low serum albumin, and male gender, was derived from this model and allowed the definition of 3 distinct risk groups. NLPHL patients presenting with histopathologic variants have a poorer outcome compared with those showing typical histology. The newly developed prognostic score combining histologic and clinical features allows allocating NLPHL patients to defined risk groups.
- Published
- 2013
- Full Text
- View/download PDF
4. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.
- Author
-
Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, Barth TE, Unterhalt M, Hiddemann W, Dreyling M, and Klapper W
- Subjects
- Biomarkers blood, Europe, Germany, Humans, Immunotherapy, Lymphoma, Mantle-Cell pathology, Multicenter Studies as Topic, Neoplasm Staging, Prognosis, Randomized Controlled Trials as Topic, Treatment Outcome, Antigens, CD20 immunology, Ki-67 Antigen blood, Lymphoma, Mantle-Cell drug therapy
- Abstract
Clinical outcome of mantle cell lymphoma (MCL) is highly heterogeneous. Tumor cell proliferation as assessed by the Ki-67 index has been shown to yield prognostic information on MCL in many studies using heterogeneously treated patient cohorts. The prognostic value of the Ki-67 index in patients treated with anti-CD20 therapy has not been studied so far. We analyzed the Ki-67 index at primary diagnosis in 249 advanced-stage MCL patients treated within randomized trials. Ki-67 showed high prognostic relevance for overall survival (relative risk 1.27 for 10% higher Ki-67, P < .001), also independently from clinical prognostic factors. The 3 groups with different Ki-67 index of less than 10%, 10% to less than 30%, and 30% or more showed significantly different overall survival in patients treated with CHOP (P = .001) as well as in patients treated with CHOP in combination with anti-CD20 therapy (R-CHOP, P = .013). Thus, the Ki-67 index remains an important prognostic marker in the era of anti-CD20 therapy. The Euro-pean MCL study is registered at www.ClinicalTrials.gov as #NCT00016887.
- Published
- 2008
- Full Text
- View/download PDF
5. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
- Author
-
Klapper W, Hoster E, Rölver L, Schrader C, Janssen D, Tiemann M, Bernd HW, Determann O, Hansmann ML, Möller P, Feller A, Stein H, Wacker HH, Dreyling M, Unterhalt M, Hiddemann W, and Ott G
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Female, Germany epidemiology, Humans, Immunohistochemistry, Interferon-alpha administration & dosage, Lymphoma, Follicular mortality, Lymphoma, Follicular therapy, Male, Middle Aged, Neoplasm Staging, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Risk Assessment, Sclerosis, Statistics, Nonparametric, Stem Cell Transplantation, Survival Analysis, Biomarkers, Tumor analysis, Lymphoma, Follicular pathology
- Abstract
Purpose: Follicular lymphoma is an indolent lymphoma with a long median overall survival. However, a considerable number of patients die within the first 2 years after the onset of the disease. Because the treatment options vary with respect to antitumor effect and potential toxic adverse effects, the identification of high-risk patients would be helpful in directing therapeutic decisions in individual patients. Several histopathologic biomarkers for risk stratification have been suggested, but most markers have not been validated in patients treated in prospective trials., Patients and Methods: We report a comprehensive approach to evaluate histopathologic biomarkers, including WHO grade, histology, and proliferation and quantitation of immune bystander cells, in 158 patients with nodal advanced-stage follicular lymphoma treated first line within a randomized trial., Results: Tumor sclerosis was a significant prognostic marker of poor overall survival that was independent of the Follicular Lymphoma International Prognostic Index (FLIPI). WHO grade, proliferation, and total T-cell or macrophage content were not associated with overall survival., Conclusion: The presence of sclerosis within the lymphoma is a marker of poor overall survival that is independent of the FLIPI. The quantification of macrophage or absolute T-cell content, grading, and proliferation are of no help in predicting the outcome of FL. Future studies need to identify surrogate markers for the prognostic immune signatures identified by gene expression profiling. Most importantly, new prognostic markers need to be confirmed in patients treated within prospective trials.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.